Today: 2 May 2026
Browse Category

NASDAQ:REGN 24 September 2025 - 29 April 2026

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
29 April 2026
···
Regeneron Stock Is Back In Focus: Why Wall Street Sees More Upside After Trump Deal

Regeneron Stock Is Back In Focus: Why Wall Street Sees More Upside After Trump Deal

Regeneron shares rose 2.6% Thursday after the company announced a U.S. drug-pricing agreement and said it would offer its new Otarmeni gene therapy free in the U.S. The stock closed at $766.02, up for the week and month but down 1.3% year to date. Raymond James and Cantor Fitzgerald reiterated bullish ratings and high price targets ahead of first-quarter results due April 29.
24 April 2026
··
Healthcare stocks brace for a busy week as XLV slips, UnitedHealth earnings and Capitol Hill heat loom

Healthcare stocks brace for a busy week as XLV slips, UnitedHealth earnings and Capitol Hill heat loom

XLV fell 0.51% to $157.48 Friday, trailing the S&P 500, which ended flat. Health insurer CEOs faced House scrutiny over rising premiums and consolidation, with UnitedHealth pledging ACA rebates in 2026. UnitedHealth reports earnings Jan. 27, Regeneron on Jan. 30. Corcept Therapeutics jumped 45% after positive ovarian cancer trial results.
24 January 2026
·····
Regeneron (REGN) Price Target Hits $1,057 as BMO and Canaccord Lift Forecasts on Dupixent Growth

Regeneron (REGN) Price Target Hits $1,057 as BMO and Canaccord Lift Forecasts on Dupixent Growth

BMO Capital raised its Regeneron price target to $850, citing Dupixent momentum and improved Eylea HD trends. Canaccord Genuity set a Street-high target of $1,057, expecting Dupixent growth to offset Eylea declines. Regeneron now holds a “Moderate Buy” consensus from 28 analysts, with an average target near $768. The stock has surged over 50% in six months amid active institutional trading.
4 December 2025
·
Regeneron Pharmaceuticals (REGN) Stock Outlook: Morgan Stanley Downgrade, Eylea HD Win and Gene‑Editing Push – December 3, 2025Regeneron

Regeneron Pharmaceuticals (REGN) Stock Outlook: Morgan Stanley Downgrade, Eylea HD Win and Gene‑Editing Push – December 3, 2025Regeneron

Regeneron shares traded near $725 midday December 3, down 2%, after Morgan Stanley downgraded the stock to Equal Weight with a $767 target, citing limited near-term upside. Eylea HD received U.S. approval for less frequent dosing in retinal vein occlusion. Market cap stands at about $77 billion, with a 0.5% dividend yield and trailing P/E of 17–18. Year-to-date total return is roughly 3%.
3 December 2025
··
NYSE Rollercoaster: Fed Caution Halts Tech Rally, Mega-Deals & Gold Spike in Wild 48 Hours

NYSE Rollercoaster: Fed Caution Halts Tech Rally, Mega-Deals & Gold Spike in Wild 48 Hours

Wall Street’s AI-fueled rally stalled Sept. 23 as the Nasdaq fell 0.95% and S&P 500 dropped 0.6% after Fed Chair Jerome Powell warned on rates and valuations. Tech stocks led declines, with Nvidia down 3% and Oracle off 4%. Gold hit a record near $3,764/oz as investors sought safety. Micron jumped 3% after strong earnings and an upbeat AI outlook.
24 September 2025
·················

Stock Market Today

  • Sastasundar Ventures Ltd (HEALTHX) Stock Overview on NSE
    May 1, 2026, 11:08 PM EDT. Sastasundar Ventures Ltd, listed on NSE as HEALTHX, operates in the healthcare and pharmaceuticals sector. The company distributes a variety of products including food supplements, herbal body care, personal care items, beverages, vitamins, and medical devices. Founded in 1989 and based in Kolkata, India, Sastasundar serves wellness and pharmaceutical markets. Investors track HEALTHX for exposure to health and wellness segments within India's growing pharmaceutical distribution space.

Latest article

US Stock Market Today After Hours: Nasdaq Tops 25,000 As S&P 500 Hits Record High

US Stock Market Today After Hours: Nasdaq Tops 25,000 As S&P 500 Hits Record High

2 May 2026
Nasdaq 100 futures climbed 0.68% and S&P 500 futures edged up 0.06% in early after-hours trading Friday, while Dow futures slipped 0.48%. The S&P 500 and Nasdaq closed at record highs, driven by first-quarter S&P 500 profit growth of 27.8%, according to LSEG. Oil prices, inflation signals, and upcoming jobs data remain in focus. GameStop shares rose 4% after reports it was preparing an offer for eBay.
McDonald’s Corporation Stock Slides Before Earnings as Its Big Drink Bet Comes Due

McDonald’s Corporation Stock Slides Before Earnings as Its Big Drink Bet Comes Due

2 May 2026
McDonald’s shares fell 2.37% to $286.64 on Friday, underperforming rivals ahead of its May 7 earnings report and a U.S. launch of six new McCafé specialty drinks. The company will begin selling the drinks nationwide on May 6, adding beverage specialist roles at 14,000 restaurants. Investors are watching whether the new drinks and value offers can boost traffic without slowing service or hurting margins.
Strategy Inc’s 11.5% STRC Payout Sets Up Bitcoin Dividend Vote

Strategy Inc’s 11.5% STRC Payout Sets Up Bitcoin Dividend Vote

2 May 2026
Strategy Inc kept STRC’s May dividend rate at 11.5% and set a $0.958333333 per-share payout, according to a new filing. Shareholders are voting on whether to move STRC dividends from monthly to twice monthly, with results due at the June 8 annual meeting. The company recently used $255 million from a stock sale to buy 3,273 bitcoin.
Go toTop